What barriers exist for using PSMA-directed CAR-T cell therapy to treat my cancer?
PSMA-directed CAR-T cell therapy is an experimental treatment for metastatic castration-resistant prostate cancer (mCRPC) that uses your own immune cells to target cancer cells. While it has shown promise in early studies, several barriers have prevented it from becoming a standard treatment. These include the tumor's ability to suppress immune cells, uneven PSMA expression on cancer cells, and challenges in keeping the CAR-T cells active long enough. Researchers are actively working on new approaches to overcome these hurdles.
What the research says
A 2026 systematic review highlights three main barriers to PSMA-directed CAR-T therapy in mCRPC 6. First, the tumor microenvironment (TME) is immunosuppressive and metabolically hostile, meaning it actively shuts down immune cells. Second, PSMA antigen heterogeneity — not all cancer cells display PSMA — allows some cells to escape treatment. Third, CAR-T cells often have limited fitness and persistence, so they may not survive or function long enough to eliminate the cancer 6.
Other studies confirm these challenges. For example, a phase I trial of a PSMA-targeted small molecule (EC1169) found that patients with a decrease in PSMA-positive circulating tumor cells had longer progression-free survival, underscoring the importance of PSMA expression 2. Similarly, a meta-analysis of lutetium-177 PSMA therapy showed that emerging new lesions after treatment were linked to worse overall survival, suggesting that antigen loss or heterogeneity can lead to treatment failure 5.
Emerging platforms aim to address these barriers. The systematic review describes next-generation approaches such as armored CAR-T cells that can reprogram the TME, as well as off-the-shelf products like iPSC-derived CAR-T cells, CAR-NK cells, and CAR-macrophages, which may offer better persistence and resistance to the TME 6. These are still in early development but represent a promising direction.
What to ask your doctor
- What clinical trials for PSMA-directed CAR-T therapy are available at this center or elsewhere?
- How does my tumor's PSMA expression level affect my eligibility for PSMA-directed therapies?
- Are there any combination treatments (like checkpoint inhibitors or TME-modifying drugs) being tested with CAR-T that might improve outcomes?
- What are the known risks and side effects of CAR-T therapy for prostate cancer, especially given the tumor microenvironment challenges?
- Should I consider other PSMA-directed treatments, such as Pluvicto (lutetium-177 PSMA), and how do they compare to CAR-T?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.